Synthesis and Preclinical Evaluation of QS-21 Variants Leading to Simplified Vaccine Adjuvants and Mechanistic Probes

• Published in: Journal of the American Chemical Society 2012-08, Vol.134 (32), p.13448-13457
• Main Authors: Chea, Eric K, Fernández-Tejada, Alberto, Damani, Payal, Adams, Michelle M, Gardner, Jeffrey R, Livingston, Philip O, Ragupathi, Govind, Gin, David Y
• Format: Article
• Language: English
• Subjects: Acylation; Adjuvants, Immunologic - chemistry; Adjuvants, Immunologic - pharmacology; Animals; Dendritic Cells - drug effects; Female; Mice; Mice, Inbred C57BL; Molecular Structure; Saponins - chemistry
• ISSN: 0002-7863; 1520-5126
• DOI: 10.1021/ja305121q

QS-21 is a potent immunostimulatory saponin that is currently under clinical investigation as an adjuvant in various vaccines to treat infectious diseases, cancers, and cognitive disorders. Herein, we report the design, synthesis, and preclinical evaluation of simplified QS-21 congeners to define key structural features that are critical for adjuvant activity. Truncation of the linear tetrasaccharide domain revealed that a trisaccharide variant is equipotent to QS-21, while the corresponding disaccharide and monosaccharide congeners are more toxic and less potent, respectively. Modification of the acyl chain domain in the trisaccharide series revealed that a terminal carboxylic acid is well-tolerated while a terminal amine results in reduced adjuvant activity. Acylation of the terminal amine can, in some cases, restore adjuvant activity and enables the synthesis of fluorescently labeled QS-21 variants. Cellular studies with these probes revealed that, contrary to conventional wisdom, the most highly adjuvant active of these fluorescently labeled saponins does not simply associate with the plasma membrane, but rather is internalized by dendritic cells.